Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study

Table 5 Sensitivity analyses

		Univariate odds ratio (95% CI)		Predictive accuracy (AUC)
Definition of advanced cancer	Number of cases/controls	Total PSA (ng/ml)	Free to total PSA (%)	Total PSA (ng/ml)	Free to total PSA (%)	Multivariable model
Metastases or ≥ T3	161/436	4.29 (2.98, 6.18)	0.92 (0.89, 0.95)	0.791	0.641	0.785
Less inclusive*	62/163	3.02 (1.87, 4.90)	0.90 (0.84, 0.95)	0.762	0.674	0.751
More inclusive†	190/512	4.05 (2.89, 5.67)	0.92 (0.89, 0.95)	0.782	0.645	0.780

* Presence of skeletal metastases at time of diagnosis.
† Presence of any of the following criteria at time of diagnosis: skeletal metastasis, clinical stage at least T3, positive lymph node, WHO grade III.

ISSN: 1741-7015